J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dal-Re, R
Right arrow Articles by Lasheras, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dal-Re, R
Right arrow Articles by Lasheras, L
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine? A comparative clinical trial in adults

R Dal-Re, A Gil, A Gonzalez, and L Lasheras

In the management of wounds, sometimes it is recommended to give an adult-type tetanus-diphtheria (Td) vaccine dose plus tetanus immune globulin (TIG). Sixty and 59 healthy young adults previously immunized against tetanus (T) and diphtheria (D) were randomized to receive intramuscularly either Td vaccine alone (group 1) or Td vaccine plus 500 IU of TIG (group 2) simultaneously. Antitoxin response was assessed after 4 weeks and 4 months. Circulating antibodies were measured by enzyme-linked immunosorbent assay (ELISA). The cutoff of these tests was 0.1 IU/mL. Titers of 0.1 IU/mL or greater were considered protective. For geometric mean titers (GMT), antibody titers below the cutoff of the assay were given, arbitrarily, 0.05 IU/mL. At 4 weeks, 98% or more of the subjects in group 1 had circulating T and D antitoxin levels of 0.1 IU/mL or higher; in group 2, 95% and 90% of the subjects had titers above this limit for T and D, respectively. At 4 months, these percentages were 98% and 95% for T antitoxin levels in groups 1 and 2, respectively; whereas 96% and 88% of the subjects in groups 1 and 2 had D antitoxin levels of 0.1 IU/mL or higher, respectively. Significantly (P < .05) higher GMTs were seen at the 4-week assessment (but not at 4 months) in group 1, as compared with group 2, in both T and D antitoxin levels (9.91 IU/mL versus 5.60 IU/mL for T antitoxin, and 2.86 IU/mL versus 1.45 IU/mL for D antitoxin). This finding resulted from those participants with low (< 0.1 IU/mL) prevaccination antibody titers.(ABSTRACT TRUNCATED AT 250 WORDS)
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
R. Forrat, R. Dumas, M. Seiberling, M. Merz, C. Lutsch, and J. Lang
Evaluation of the Safety and Pharmacokinetic Profile of a New, Pasteurized, Human Tetanus Immunoglobulin Administered as Sham, Postexposure Prophylaxis of Tetanus
Antimicrob. Agents Chemother., February 1, 1998; 42(2): 298 - 305.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American College of Clinical Pharmacology